95 results about "Trastuzumab" patented technology

Protein recognized by an antibody used as an active ingredient of an antibody medicine such as trastuzumab or an antibody used for targeting a target site of an active ingredient is highly accurately quantitatively determined by employing a quantitative tissue staining method of biological tissues, thereby providing a method for determining therapeutic effectiveness of a medicine containing such an antibody as a component. The effectiveness of a medicine containing an antibody as a component is determined by employing a tissue staining method comprising the steps of: labeling the antibody in the medicine containing an antibody as a component with a fluorescent material and contacting the thus fluorescence-labeled antibody with a tissue sample; obtaining a fluorescence image by irradiating, with excitation light, a tissue site contacted with the antibody; obtaining an autofluorescence image in the same field of view and at the same focus as in the fluorescence image in a close region on a shorter wavelength side or a longer wavelength side of an acquisition wavelength region of fluorescence emitted by the fluorescent material; obtaining a corrected fluorescence image by performing image processing for removing fluorescence brightness of the autofluorescence image from fluorescence brightness of the fluorescence image; counting the number of cells in the tissue site contacted with the antibody; measuring average fluorescence brightness per fluorescent particle; and calculating the number of fluorescent particles per cell.

Methods of treating patients having metastatic or unresectable locally advanced HER2 positive cancer, e.g., breast cancer, with the antibody-drug conjugate trastuzumab-MCC-DM1 are provided, wherein the patients have received extensive prior treatment, e.g., with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab.

The invention discloses a preparation method of agarose immune magnetic microspheres and applications thereof, and relates to a preparation method of microspheres and applications thereof, which solves the technical problems that an existing purified monoclonal antibody is complex in process, is low in yield, and is high in cost, and coupling agents are hypertoxic. The preparation method comprises the following steps of: 1. preparing a ferric oleate precurser; 2. preparing a magnetic fluid; 3. preparing an oil phase and a water phase; 4. preparing agarose magnetic microspheres; 5. preparing activated and crosslinked agarose magnetic microspheres; 6. preparing agarose magnetic microspheres joined with spacer arms; and 7. preparing agarose immune magnetic microspheres. The agarose immune magnetic microspheres provided by the invention are used for purifying genetic engineering recombination trastuzumab monoclonal antibodies. The agarose immune magnetic microspheres prepared by the invention are used for the field of separating and purifying the monoclonal antibodies.

The invention relates to methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of neoplastic disease. Neoplastic disease is often caused by chromosomal rearrangements which lead to over- or underexpression of the rearranged genes. The invention discloses genes which are overexpressed in neoplastic tissue and are useful as diagnostic markers and targets for treatment. Methods are disclosed for predicting, diagnosing and prognosing as well as preventing and treating neoplastic disease.

Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.

Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.

The present invention provides an agent for preventing or treating a trastuzumab-resistant cancer, which contains one or more medicaments selected from a cofilin inhibitor, a PAK1 inhibitor, a LIMK inhibitor, a RHO inhibitor, a ROCK1 inhibitor and a ROCK2 inhibitor.

Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering either i) an effective amount of an anti-estrogen agent or ii) an effective amount of a receptor tyrosine kinase inhibitor and an effective amount of a bispecific anti-ErbB2 / anti-ErbB3 antibody, and optionally an effective amount trastuzumab. Also disclosed is a bispecific anti-ErbB2 / anti-ErbB3 antibody for use in the therapy of a tumor in combination with either i) an anti-estrogen agent or ii) a receptor tyrosine kinase inhibitor, and optionally in use with trastuzumab.

The present invention relates to a fusion protein resulting from the fusion of a cancer-specific antibody and an angiogenesis inhibitor, and relates to an anti-cancer composition including the same. More specifically, in the present invention, it is preferable that the cancer-specific antibody is trastuzumab or a fragment thereof, and the angiogenesis inhibitor is a VEGF-Trap. When the fusion protein according to the present invention is used, there are advantages in that angiogenesis and cancer cell growth can be effectively inhibited as compared to trastuzumab or VEGF-Trap, and side effects can also be reduced.

The present invention provides methods for identifying cancer patients susceptible to effective treatment with trastuzumab and other medications that function similarly to trastuzumab. The invention is based on the discovery that certain chromosomal abnormalities can be used to selectively identify cancer patients that are likely to be successfully treated with medication that inhibits the signaling capability of the HER-2 receptor protein or otherwise function similarly to trastuzumab. The invention is based on the use of nucleic acid technology where nucleic acid probes are allowed to hybridize to cell samples and the number of copies of particular genetic regions quantified. The present invention also provides kits and sets of probes for use in identifying cancer patients susceptible to effective treatment with trastuzumab and other medications that function similarly to trastuzumab.

The expression of Her-2 / neu protein on circulating cancer cells in a blood sample is detected by isolating the cancer cells from the blood sample and then performing on the isolated cancer cells a sensitive Her-2 / neu immunoassay. A positive result indicates the expression of Her-2 / neu on cancer cells in the blood sample. This method can be used to identify cancer patients who are likely to benefit from treatment with an anticancer agent that targets Her-2 / neu, such as trastuzumab (HERCEPTIN).

The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.

The anticancer medicine composition containing tyrosine kinase inhibitor is slow released injection and slow released implant. The effective anticancer components include tyrosine kinase inhibitor selected from Erbitux, Iressa, Tarceva, Sunitinib, Trastuzumab, etc, and / or composition selected from Docetaxel, deacetyl taxol, taxol, etc. The slow releasing supplementary material is selected from p(LAEG-EOP), p(DAPG-EOP), etc. The released injection and slow released implant may be injected or set in tumor for slow releasing to maintain effective medicine concentration for over 50 days, and has obviously lowered systemic reaction on the medicine and capacity of enhancing the chemotherapeutic and radiotherapeutic effect.

Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (BBB) and / or improve tissue penetration of the antibody in CNS and peripheral tissues, and thereby treat and / or diagnose HER2-positive cancers, including those of the central nervous system (CNS).

The invention relates to the fields of therapeutics and identifying candidates for therapy, in particular to a method of identifying candidates for trastuzumab (Herceptin®) therapy in a patient presenting with breast cancer based on the presence or absence of specific genetic markers in a tumor sample from said patient.

The invention discloses a trastuzumab drug-resistant human breast cancer cell line BT-474 / HR. The human breast cancer cell line has the collection number of CCTCC NO:C2014245 in China Center for Type Culture Collection, and the collection date of the human breast cancer cell line is 14, January in 2015. The invention also discloses a method for constructing the trastuzumab drug-resistant human breast cancer cell line BT-474 / HR. The method comprises the following step of preparing a human breast cancer cell line BT-474 / HR with excellent in-vitro and in-vivo trastuzumab drug resistance by utilizing a human breast cancer cell line BT-474 and combining two means of in-vitro induction and in-vivo induction of trastuzumab. According to the cell line, the HER2 overexpression characteristics of a parental cell line are remained, and the cell line has excellent in-vitro and in-vivo drug resistance on an HER2 targeted antibody drug. Therefore, the human breast cancer cell line can be directly applied to development and research of novel anti-tumor treatment drugs.

A method of treating cancer by co-administering a therapeutic monoclonal antibody and IL-21 is described. Exemplary monoclonal antibodies that may be used are rituximab, trastuzumab, and anti-CTLA-4 antibodies. For patient populations resistant to monoclonal antibody therapy, relapsed after treatment with monoclonal antibodies, or in which enhanced IL-21 antitumor effects reduce toxicity associated with therapy with monoclonal antibodies, the The enhanced antitumor properties of the combination therapy described above are particularly useful.

Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.

The anticancer composition containing tyrosine kinase inhibitor is slow released injection and slow released implanted preparation. Its effective anticancer component is the composition of Erbitux, Iressa, Tarceva, Sunitinib, Trastuzumab and other tyrosine kinase inhibitor, and Edelfosine, miltefosine, perifosine, ilmofosine and other phosphoinositide-3-kinase inhibitor. Its slow releasing supplementary material is selected from p(LAEG-EOP), p(DAPG-EOP), other polyphosphate copolymer, poly(erucic acid dipolymer-sebacic acid), etc. The anticancer composition may injected or set into tumor and can maintain the effective medicine concentration for over 50 days with obviously reduced general reaction and capacity of raising the treating effect of chemotherapeutic and / or radiotherapeutic medicine.

Systems and methods for producing liposomes, including control liposomes and immunoliposomes targeting breast cancer are provided. Systems and methods for treating breast cancer, using targeted immunoliposomes produced according to various methods are also disclosed herein. For example, trastuzumab-conjugated immunoliposomes may be used to deliver chemotherapeutic agents to breast cancer tissues for the treatment of breast cancer. Systems and methods for actuating liposomes using ultrasound are also disclosed, such as systems and methods for actuating trastuzumab-conjugated liposomes accumulated in breast cancer tissues for the treatment of breast cancer.

The invention discloses an affinity peptide specific to herceptin and a segment thereof, belonging to the technical field of biology. The structure of the peptide is R1-X-R2, wherein R1 is NH2, R2 is COOH, and X is a peptide segment from 3 peptides to 18 peptides and is preferably 4 peptides or 6 peptides. The affinity peptide is coupled to a carrier so as to separate and purify herceptin and the segment thereof. The invention can overcome the defects of high cost, poor stability and insufficient safety of the traditional ligand, and has the advantages of high affinity, high specificity, quick herceptin capture, low production cost, low immunogenicity, high chemical stability and the like. The affinity peptide has excellent application prospects and can produce great social benefits and economical benefits.

The invention discloses a protein stationary phase modification open tubular column and application of the protein stationary phase modification open tubular column to monoclonal antibody charge isomer separation. The open tubular column is prepared through the following steps that PDDA is fixed on the inner wall of a capillary tube by an electrostatic self-assembly method; then, protein is adsorbed on the PDDA surface through electrostatic self assembly; the protein stationary phase modification open tubular column is obtained. The open tubular column shows specific selectivity on monoclonal antibody charge isomers. Seven kinds of different-form charge isomers of cetuximab are successfully separated; two alkaline isomers and one acid isomer of the rituximab and two alkaline charge isomers and four acid isomers of trastuzumab are successfully separated from main peaks.

Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.

The invention provides a nuclide marked trastuzumab monoclonal antibody as well as a preparation method and application thereof. Through radionuclide 124I marking, a corresponding radioactive moleculeprobe 124I-Trastuzumab is obtained and is combined with HER2, so that tumor tissue with high expression of HER2 can be accurately positioned by nuclear medicine means, and the purposes of disease targeted molecule image diagnosis and treatment can be achieved.

The invention provides a set of markers for predicting sensibility of HER2 positive metastatic breast cancer patients to trastuzumab. The set of markers comprises miR-451a, miR-16-5p, miR-17-3p and miR-940. The invention further provides a kit and system for predicting the sensibility of the HER2 positive metastatic breast cancer patients to the trastuzumab. The treatment effect of the trastuzumabis predicted through change of the amount of microRNA in serum, and the sensibility of the HER2 positive metastatic breast cancer patients to the trastuzumab can be predicted well through the system.

The invention discloses an anti-human ErbB2 bispecific antibody as well as a preparation method and application thereof. The anti-human ErbB2 bispecific antibody provided by the invention is prepared by linking a single chain antibody of anti-human ErbB2 to the N-terminal of the heavy chain of the Trastuzumab antibody through linker peptides; the heavy chain variable region in the single-chain antibody is a heavy chain variable region of an HuA21 antibody; a light chain variable region in the single chain antibody is a light chain variable region of an HuA21 antibody; the amino acid sequence of the linker peptides is the 275th to 289th sites in the sequence I of the sequence table. The anti-human ErbB2 bispecific antibody provided by the invention has a good antitumor effect and has a more excellent endocytosis effect than the original Trastuzumab antibody and the HuA21 antibody, so that the anti-human ErbB2 bispecific antibody is of great significance as used for preparing antibody targeting drugs as a drug carrying tool.